The UK's National Institute for Health and Clinical Excellence (NICE) are in the process of reviewing rimonabant for the treatment of overweight and obese adults.
The Appraisal Committee are due to meet again early next year to produce a Final Appraisal Determination but the preliminary recommendations indicate that NICE is unlikely to recommend rimonabant.
They have requested additional information from the manufacturer to include evidence from the clinical trials on health outcomes (including cardiovascular risk factors) and evidence on the cost effectiveness of rimonabant compared with diet and exercise alone, as well as the cost effectiveness of rimonabant compared with orlistat and sibutramine.
Hat tip: Matt
No comments:
Post a Comment